MeredithChukMDMSc

Pediatric Hematology & Oncology • Silver Spring, MD

Medical Advisor

Join to view full profile

Dr. Chuk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chuk's full profile

Already have an account?

Office
FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993

Education & Training

Duke UniversityMS, clinical research, 2009
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2005 - 2008
National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 2005 - 2008
UPMC Medical EducationResidency, Pediatrics, 2001 - 2004
Pennsylvania State University College of MedicineClass of 2001

Certifications & Licensure

MD State Medical License 2006 - 2026
PA State Medical License 2004 - 2016
WV State Medical License 2011 - 2014

Publications & Presentations

PubMed

44 citations
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children...
Meredith K. Chuk, Brigitte C. Widemann, Charles G. Minard, Xiaowei Liu, Ae Rang Kim
Pediatric Blood & Cancer. 2018-08-01
85 citations
A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents W...
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, Meredith K. Chuk, Eva Dombi
Journal of Clinical Oncology. 2010-12-10
55 citations
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
May Tun Saung, Lorraine Pelosof, Sandra Casak, Martha Donoghue, Steven Lemery
The Oncologist. 2021-09-01

Abstracts/Posters

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis
Meredith Chuk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Houston Methodist and U.S. Department of Health and Human Services Partner to Expand Access to COVID-19 Monoclonal Antibody TreatmentMay 27th, 2021
UPMC on Expanded Eligibility Guidelines for COVID-19 Treatment – Pittsburgh, PennsylvaniaMay 26th, 2021
UPMC Touts Antibody Treatment for Covid-19May 26th, 2021
Join now to see all